When did MindMaze Therapeutics announce the Annual General Meeting results?

MindMaze Therapeutics announced the results on 25 June 2026. The release said the Annual General Meeting had been held earlier that day.

What happened to MindMaze Therapeutics’ proposed increase in conditional share capital?

Shareholders did not approve MindMaze Therapeutics’ proposed increase in conditional share capital because it did not obtain the required qualified majority.

Which existing directors were re-elected at MindMaze Therapeutics’ Annual General Meeting?

Walid Hanna, Olaf Blanke and Martin Reiss were re-elected to MindMaze Therapeutics’ Board of Directors.

Who were the new directors elected to MindMaze Therapeutics’ Board?

Shareholders elected Brad Hollinger and Zach Henderson as new members of MindMaze Therapeutics’ Board of Directors. Brad Hollinger is identified as Founder, Chairman and Chief Executive Officer of Vibra Healthcare, while Zach Henderson is identified as Chief Executive Officer of MindMaze Therapeutics.

Who was re-elected as Chairman of MindMaze Therapeutics’ Board of Directors?

Walid Hanna was re-elected as Chairman of MindMaze Therapeutics’ Board of Directors.

Which financial and governance proposals did shareholders approve at MindMaze Therapeutics’ Annual General Meeting?

Shareholders approved the 2025 Annual Report and financial statements, the appropriation of available earnings and the discharge of the members of the Board of Directors and the Executive Committee. They also approved the elections to the Nomination and Compensation Committee, the re-election of the Independent Proxy and the statutory auditor.

What compensation-related proposals did MindMaze Therapeutics shareholders approve?

Shareholders approved the compensation proposals for the Board of Directors and Executive Committee, as well as the consultative vote on the 2025 Compensation Report.

When will MindMaze Therapeutics publish the detailed voting results?

MindMaze Therapeutics said detailed voting results would be published on the Company’s website later today.

What does MindMaze Therapeutics do?

MindMaze Therapeutics describes itself as a global leader in scalable, precision neurotherapeutics. It integrates advanced software, proprietary sensors and AI-driven data analytics to provide care from the acute hospital phase through outpatient treatment and home-based therapy.

Which conditions do MindMaze Therapeutics’ products address?

MindMaze Therapeutics says its FDA-cleared and CE-marked products are designed to provide scalable, reimbursable solutions for stroke, Parkinson’s disease and other neurological disorders.

Where are MindMaze Therapeutics’ shares listed and what is the ticker symbol?

MindMaze Therapeutics is identified in the source as listed on SIX under the ticker symbol MMTX.

Home
News Intelligence
MindMaze Therapeutics Holding SA
MindMaze Therapeutics reports AGM outcome as conditional capital proposal fails to secure majority

Back to all MindMaze Therapeutics Holding SA press releases

MindMaze Therapeutics Holding SA

OTCQB:MMTZF
SIX:MMTX

MindMaze Therapeutics reports AGM outcome as conditional capital proposal fails to secure majority

Published Thursday, 25 June 2026, 10:50 AM

Get alerts

Plain English summaries when MindMaze Therapeutics Holding SA announces news.

At a glance

Company: MindMaze Therapeutics Holding SA
Listings: OTCQB:MMTZF, SIX:MMTX
Announcement type: Corporate update
Published: Thursday, 25 June 2026, 10:50 AM
Source announcement: eqs-news.com

FAQSIR Generated from this announcement View original release below for safe harbor and regulatory notices

Announcement Summary

MindMaze Therapeutics Holding SA (SIX: MMTX) announced the results of its Annual General Meeting.

Board proposals passed except proposed conditional share capital increase; required qualified majority was not obtained.
Walid Hanna, Olaf Blanke and Martin Reiss were re-elected to the Board of Directors.
Brad Hollinger and Zach Henderson were elected to the Board of Directors.
The Company said detailed voting results will be published on its website later today.

Shareholders approved 2025 Annual Report, financial statements, earnings, discharges, Chairman and committee elections, Independent Proxy, statutory auditor, compensation proposals and consultative 2025 Compensation Report vote.

Investor FAQs

MindMaze Therapeutics announced the results of its Annual General Meeting, saying shareholders approved all proposals submitted by the Board of Directors except the proposed increase in conditional share capital. The increase did not obtain the required qualified majority.

Source announcement

Company: MindMaze Therapeutics Holding SA
Title: MindMaze Therapeutics Announces Results of Annual General Meeting
Published: Thursday, 25 June 2026, 10:50 AM
Source site: eqs-news.com

Read the source announcement on eqs-news.com

FAQSIR's summary and investor FAQs are generated by AI from the text of this announcement alone, without information from other sources.

Figures, forecasts and other claims are the announcement's, not FAQSIR's. FAQSIR does not independently verify them.

Read the original press release

Full text as published, unedited.

Loading the original release…

Important Notice And Disclaimer

This article was generated by an artificial intelligence system from an announcement published by the issuer. It has not been independently researched, verified, or edited by a journalist, and no person holds editorial responsibility for its wording.

The issuer named in this article has not paid for this page and has no commercial relationship with its publisher. This is an unpaid evaluation preview produced from announcements the issuer published publicly, and it is not independent editorial coverage.

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Ask about this announcement

Answers drawn only from this announcement

Reading the announcement…